Asset profile
Suzetrigine
Small molecule
Evidence outlook
Approved: Acute Pain
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Diabetic Peripheral Neuropathic Pain · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
15 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 13 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Suzetrigine: this drug | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| JMKX000623 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| VX-993 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | ||
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | ||
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | ||
| Tapentadol | Approved | Small molecule | Mu-opioid receptor and norepinephrine transporter (NET) | ||
| Crisugabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| Mirogabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| HL-1186 | Phase 2/3 | Small molecule | — | ||
| HRS-2129 | Phase 2/3 | Small molecule | — | ||
| LY4065967 | Phase 2 | Small molecule | Angiotensin II type 2 receptor (AT2R) (antagonist) | ||
| NRD135S.E1 | Phase 2 | Small molecule | — | ||
| Pilavapadin | Phase 2 | Small molecule | AP2-associated kinase 1 (AAK1) | ||
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3), Muscarinic M1 receptor (antagonist) | ||
| AJH-2947 | Phase 1 | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (13)
January 2027 (3)
What to watch
What to watch
February 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (2)
July 2027 (2)
August 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
February 2028 (1)
What to watch
August 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.